MX2022004635A - Agente reductor de toxina uremica. - Google Patents

Agente reductor de toxina uremica.

Info

Publication number
MX2022004635A
MX2022004635A MX2022004635A MX2022004635A MX2022004635A MX 2022004635 A MX2022004635 A MX 2022004635A MX 2022004635 A MX2022004635 A MX 2022004635A MX 2022004635 A MX2022004635 A MX 2022004635A MX 2022004635 A MX2022004635 A MX 2022004635A
Authority
MX
Mexico
Prior art keywords
reducing agent
uremic toxin
bacteria
toxin reducing
total cholesterol
Prior art date
Application number
MX2022004635A
Other languages
English (en)
Spanish (es)
Inventor
Yoshiki Tanaka
Ayako Maeda
Shunji Nakajima
Takaaki Abe
Original Assignee
Biofermin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofermin Pharmaceutical Co Ltd filed Critical Biofermin Pharmaceutical Co Ltd
Publication of MX2022004635A publication Critical patent/MX2022004635A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022004635A 2019-10-21 2020-10-20 Agente reductor de toxina uremica. MX2022004635A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019191754 2019-10-21
PCT/JP2020/039359 WO2021079869A1 (ja) 2019-10-21 2020-10-20 尿毒素軽減剤

Publications (1)

Publication Number Publication Date
MX2022004635A true MX2022004635A (es) 2022-05-10

Family

ID=75620690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004635A MX2022004635A (es) 2019-10-21 2020-10-20 Agente reductor de toxina uremica.

Country Status (8)

Country Link
US (1) US20220387526A1 (cg-RX-API-DMAC7.html)
EP (1) EP4049667A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2021079869A1 (cg-RX-API-DMAC7.html)
CN (2) CN118252856A (cg-RX-API-DMAC7.html)
MX (1) MX2022004635A (cg-RX-API-DMAC7.html)
PH (1) PH12022550966A1 (cg-RX-API-DMAC7.html)
TW (1) TWI870485B (cg-RX-API-DMAC7.html)
WO (1) WO2021079869A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102362828B1 (ko) * 2021-06-17 2022-02-15 주식회사 비피도 비피도박테리움 비피덤 bgn4를 함유한 신부전 개선용, 치료용 또는 예방용 조성물
JP7504490B2 (ja) * 2022-09-01 2024-06-24 合同会社AiMIYA 重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤
CN115887483B (zh) * 2022-09-29 2025-12-16 百施(上海)生物科技有限公司 发酵乳杆菌cect 5716胞外多糖在制备预防或改善慢性肾脏疾病中的应用
CN115887502A (zh) * 2022-11-29 2023-04-04 中国人民解放军空军军医大学 粪副拟杆菌在制备防治心力衰竭药物中的应用
CN116585360B (zh) * 2023-05-24 2023-11-14 微康益生菌(苏州)股份有限公司 一种改善慢性肾病的益生菌剂及其应用
CN120330113B (zh) * 2025-06-23 2025-09-16 上海菌济健康科技有限公司 具有尿酸降解及护肾作用的乳酸片球菌pa3-7及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61271223A (ja) * 1985-05-24 1986-12-01 Biofuerumin Seiyaku Kk 血中脂質改善剤
JPH09110707A (ja) * 1995-10-12 1997-04-28 Wakamoto Pharmaceut Co Ltd 慢性腎不全改善剤および透析患者のクオリティー オブ ライフ改善剤
JP2003252772A (ja) * 2002-03-04 2003-09-10 Snow Brand Milk Prod Co Ltd 加齢に伴う代謝異常症の予防・改善・治療剤
JP2004277296A (ja) * 2003-03-13 2004-10-07 Morishita Jintan Kk 乳酸菌含有腸溶性製剤
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
EP2221360B1 (en) * 2007-11-30 2014-03-05 Meiji Co., Ltd. Lactic acid bacterium having effect of lowering blood uric acid level
WO2011114916A1 (ja) * 2010-03-18 2011-09-22 森永乳業株式会社 貧血の予防又は治療用組成物
CN102959075B (zh) * 2010-07-05 2016-03-02 株式会社明治 具有肠内腐败物质的减少作用的双歧杆菌
ES2436251B1 (es) * 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
TWI481409B (zh) 2013-01-10 2015-04-21 Conmed Pharmaceutical & Bio Medical Corp 一種使用益生菌製備用於清除尿毒素之組合物的用途
PT3071235T (pt) * 2015-01-26 2018-02-21 Kaleido Biosciences Inc Produtos terapêuticos de glicanos e respetivos métodos relacionados
AU2017287988B2 (en) * 2016-06-30 2024-08-01 Asahi Group Holdings, Ltd. Renal anemia ameliorating composition
CN110267670B (zh) * 2016-10-20 2023-08-15 表飞鸣制药株式会社 对肠道的离子跨细胞转运体的作用剂、氯离子通道活化剂、肾脏疾病的预防或治疗剂或者排便促进剂
WO2019087842A1 (ja) * 2017-11-01 2019-05-09 ビオフェルミン製薬株式会社 非ステロイド性抗炎症薬及びプロトンポンプ阻害薬誘発性小腸障害の予防又は治療剤

Also Published As

Publication number Publication date
WO2021079869A1 (ja) 2021-04-29
PH12022550966A1 (en) 2023-09-25
JPWO2021079869A1 (cg-RX-API-DMAC7.html) 2021-04-29
US20220387526A1 (en) 2022-12-08
CN114585375A (zh) 2022-06-03
EP4049667A1 (en) 2022-08-31
CN118252856A (zh) 2024-06-28
EP4049667A4 (en) 2024-02-21
TWI870485B (zh) 2025-01-21
TW202123949A (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
PH12022550966A1 (en) Uremic toxin reducing agent
WO2019118515A3 (en) Compositions and methods for suppressing pathogenic organisms
EP4272815A3 (en) New medical use of probiotics
IL291460A (en) Bacterial strains, their compositions and their use in the treatment of gastrointestinal disorders
MA41013B1 (fr) Compositions comprenant des souches bactériennes
NZ711771A (en) Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
WO2020120714A8 (en) Compositions comprising bacterial strains
PH12017502042A1 (en) Dietary supplement
PT4031157T (pt) Estirpes bacterianas, suas composições e sua utilização para o tratamento de perturbações gastrointestinais
EP4628063A3 (en) Modular exoskeleton for example for spinal cord injured patients
EP4005579A4 (en) COMPOSITION WITH LACTOBACILLUS REUTERI ATG-F4 FOR THE PREVENTION OR TREATMENT OF MUSCLE DISEASES
GEP201706775B (en) Method for selection of agents influencing intestinal motility disorders and pain
GB201815025D0 (en) Insect-pathogenic fungus, spores, composition and use of same
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
SG11202103103TA (en) Gdsl lipase, genetically-engineered bacteria and application thereof
MX2021006185A (es) Combinacion de probioticos para el tratamiento de trastornos alergicos.
AU2018282018A1 (en) Compositions and methods for reducing flatulence
AU2019213029B2 (en) Bifidobacterium longum NCIMB 41676
MX2020007671A (es) Terapia de combinacion para tratar o prevenir el cancer.
WO2021004958A3 (en) Compositions comprising bacterial strains
MX2020007664A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2025012889A (es) Composiciones que comprenden consorcios bacterianos
EP3950929A4 (en) FAECALIBACTERIUM SP. MICROBE AND ANTI-CANCER COMPOSITION WITH IT
MX2019006086A (es) Uso de una composicion bacteriana para tratar infecciones en las patas de ungulados.
BR112019002023A2 (pt) prevenção ou tratamento de infecções antifúngicas vetorizado por bactérias probióticas